MedTrace Logo

Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.

NCT04078126 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2022-03-18

Study results available
· View outcomes & findings →

Summary

Study comparing the same drugs as a dual combination product (budesonide and formoterol) given via two different inhalers. To see which one results in the best effect on breathing.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

COMBINATION_PRODUCT

BFF

Treatment with budesonide and formoterol furmate MDI (metered-dose inhaler)

COMBINATION_PRODUCT

Symbicort Turbuhaler

Treatment with budesonide and formoterol furmate DPI (dry-powder inhaler)

Sponsors & Collaborators

Principal Investigators

  • Bärbel Huber, Dr. · 2601

  • Heiner Steffen, Dr. · 2602

  • Claus Keller, Dr. · 2603

  • Martin Hoffmann, Dr. · 2604

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-10
Primary Completion
2020-12-30
Completion
2020-12-30
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04078126 on ClinicalTrials.gov